Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 170 entries
View as:

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

Phase: N/A Priority: Normal
NCT ID: NCT02772081 Org: User:
Start: 05/18/21 End: 08/13/22 Due: 08/13/23

2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients

Phase: N/A Priority: Normal
NCT ID: NCT02579850 Org: User:
Start: 05/29/15 End: 07/10/17 Due: 07/10/18

Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00497237 Org: User:
Start: 04/30/07 End: 03/31/10 Due: 03/31/11

Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients

Phase: N/A Priority: Normal
NCT ID: NCT01345916 Org: User:
Start: 03/31/11 End: 08/31/11 Due: 08/31/12

Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study

Phase: N/A Priority: Normal
NCT ID: NCT00501982 Org: User:
Start: 03/31/07 End: 05/31/08 Due: 05/31/09

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Phase: N/A Priority: Normal
NCT ID: NCT05292586 Org: User:
Start: 10/05/22 End: 06/24/24 Due: 06/24/25

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF

Phase: N/A Priority: Normal
NCT ID: NCT05513950 Org: User:
Start: 01/25/23 End: 06/17/24 Due: 06/17/25

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT03084796 Org: User:
Start: 07/28/17 End: 06/06/18 Due: 06/06/19

Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT00742248 Org: User:
Start: 09/30/04 End: 05/31/05 Due: 05/31/06

Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

Phase: N/A Priority: Normal
NCT ID: NCT06264674 Org: User:
Start: 11/27/23 End: 02/24/25 Due: 02/24/26

Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's Adherence

Phase: N/A Priority: Normal
NCT ID: NCT03951714 Org: User:
Start: 08/12/19 End: 07/06/20 Due: 07/06/21

Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001

Phase: N/A Priority: Normal
NCT ID: NCT03004495 Org: User:
Start: 01/31/16 End: 08/31/16 Due: 08/31/17

A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis

Phase: N/A Priority: Normal
NCT ID: NCT04010799 Org: User:
Start: 05/27/19 End: 03/08/21 Due: 03/08/22

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.

Phase: N/A Priority: Normal
NCT ID: NCT02040597 Org: User:
Start: 01/31/14 End: 04/30/15 Due: 04/30/16

Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT02467452 Org: User:
Start: 05/31/15 End: 01/31/17 Due: 01/31/18

Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration

Phase: N/A Priority: Normal
NCT ID: NCT01176903 Org: User:
Start: 08/31/10 End: 08/31/11 Due: 08/31/12

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

Phase: N/A Priority: Normal
NCT ID: NCT01730404 Org: User:
Start: 10/31/12 End: 10/31/13 Due: 10/31/14

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

Phase: N/A Priority: Normal
NCT ID: NCT03378648 Org: User:
Start: 12/28/17 End: 04/16/19 Due: 04/16/20

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Phase: N/A Priority: Normal
NCT ID: NCT03566017 Org: User:
Start: 09/16/18 End: 01/21/25 Due: 01/21/26

Registry Study of Revcovi Treatment in Patients With ADA-SCID

Phase: N/A Priority: Normal
NCT ID: NCT03878069 Org: User:
Start: 09/30/19 End: 01/18/23 Due: 01/18/24

Functional Respiratory Imaging Study (FRI)

Phase: N/A Priority: Normal
NCT ID: NCT03268226 Org: User:
Start: 11/20/17 End: 01/30/19 Due: 01/30/20

Dose Finding Study of CHF 4226 for Treating Patients With COPD

Phase: N/A Priority: Normal
NCT ID: NCT00605891 Org: User:
Start: 10/31/06 End: 06/30/07 Due: 06/30/08

Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00868023 Org: User:
Start: 02/28/09 End: 10/31/09 Due: 10/31/10

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

Phase: N/A Priority: Normal
NCT ID: NCT02676076 Org: User:
Start: 02/17/16 End: 05/17/18 Due: 05/17/19

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Phase: N/A Priority: Normal
NCT ID: NCT06663358 Org: User:
Start: 11/06/24 End: 11/30/29 Due: 11/30/30